TRASTUZUMAB DERUXTECAN
Information current as at: 1 May 2024
Submission Details
- Brand name:
-
- Enhertu®
- Pharmaceutical company:
- AstraZeneca Pty Ltd
- Condition/indication:
(therapeutic use) -
- Breast cancer
- PBAC Submission type:
- New listing (Early Resolution Pathway)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – March 2023
- Related medicines:
Progress Details
-
Submission received for: - March 2023 PBAC meeting
-
Opportunity for consumer comment: - --
-
PBAC meeting: - Held on 08/03/2023
-
Lodgement of required documentation: - 13/04/2023
-
Acceptance of complete documentation:
- Accepted
-
Agreement to listing arrangements: - Commenced on 15/06/2023
-
Status:
- Finalised
-
Government processes: - Commenced on 14/07/2023
-
Medicine listed on the PBS: - 01/11/2023 (see PBS schedule)
Case ID: a693
Page last updated: 02 May 2024